Catarina Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Catarina Santos has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ana Duarte Mendes
Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
2 shared publications - Diogo Alpuim Costa
Oncology Functional Unit, Hospital de Cascais (Alcabideche), Cascais, Portugal
2 shared publications - Guida Da Ponte
Unidade Local de Saúde do Arco Ribeirinho
2 shared publications - Marina Vitorino
Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
2 shared publications - Rodrigo Vicente
Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, 2720-276 Amadora, Portugal
2 shared publications Ana Rita Garcia
Medical Oncology, Portuguese Oncology Institute of Coimbra, Coimbra, Portugal
1 shared publication
Latest Publications
- 10 September 2026
- Published by Wiley in Counselling and Psychotherapy Research
- Vol. 26 (3)
Development and Preliminary Evaluation of a Culturally Adapted Meaning‐Centred Psychotherapy Intervention for Physicians in Portugal
Background: Healthcare professionals (HCPs) are particularly vulnerable to burnout and moral distress, increasingly associated with a crisis of meaning in clinical practice. Meaning‐Centred Psychotherapy (MCP) has emerged as a promising approach to address these challenges; however, its application among HCPs remains limited. This study aimed to develop and evaluate a culturally adapted MCP intervention for physicians in Portugal (MCP–HCP‐P). Methods: A sequential mixed methods design was conducted. Phase 1 involved a focus group () to assess feasibility and inform adaptation. Phase 2 comprised intervention reformulation. Phase 3 consisted of a pilot trial () evaluating preliminary effectiveness and applicability. Outcomes included meaning in life, moral distress, burnout, resilient coping and meaningful work, assessed at baseline, post‐intervention and 1‐month follow‐up. Qualitative data explored therapeutic mechanisms. Results: Participants favoured a biweekly, group‐based, predominantly in‐person format with heterogeneous composition. The adapted intervention included four sessions and a culturally tailored reflection on life and death. Moral distress decreased over time, while burnout and coping remained stable. The intervention was well received, with approximately two‐thirds rating it as useful. Lack of time was the main barrier, while protected time, leadership support, and trained facilitators were key enablers. Qualitative findings identified identity, particularly teamwork and integration of professional and personal identity, as the central source of meaning. Conclusions: MCP–HCP‐P appears feasible, acceptable and potentially beneficial, particularly in reducing moral distress and supporting meaning‐making. Addressing existential dimensions of clinical work may enhance HCP well‐being and inform multilevel interventions.
- 10 September 2026
- Published by Wiley in Counselling and Psychotherapy Research
- Vol. 26 (3)
Development and Preliminary Evaluation of a Culturally Adapted Meaning‐Centred Psychotherapy Intervention for Physicians in Portugal
Background: Healthcare professionals (HCPs) are particularly vulnerable to burnout and moral distress, increasingly associated with a crisis of meaning in clinical practice. Meaning‐Centred Psychotherapy (MCP) has emerged as a promising approach to address these challenges; however, its application among HCPs remains limited. This study aimed to develop and evaluate a culturally adapted MCP intervention for physicians in Portugal (MCP–HCP‐P). Methods: A sequential mixed methods design was conducted. Phase 1 involved a focus group () to assess feasibility and inform adaptation. Phase 2 comprised intervention reformulation. Phase 3 consisted of a pilot trial () evaluating preliminary effectiveness and applicability. Outcomes included meaning in life, moral distress, burnout, resilient coping and meaningful work, assessed at baseline, post‐intervention and 1‐month follow‐up. Qualitative data explored therapeutic mechanisms. Results: Participants favoured a biweekly, group‐based, predominantly in‐person format with heterogeneous composition. The adapted intervention included four sessions and a culturally tailored reflection on life and death. Moral distress decreased over time, while burnout and coping remained stable. The intervention was well received, with approximately two‐thirds rating it as useful. Lack of time was the main barrier, while protected time, leadership support, and trained facilitators were key enablers. Qualitative findings identified identity, particularly teamwork and integration of professional and personal identity, as the central source of meaning. Conclusions: MCP–HCP‐P appears feasible, acceptable and potentially beneficial, particularly in reducing moral distress and supporting meaning‐making. Addressing existential dimensions of clinical work may enhance HCP well‐being and inform multilevel interventions.
- 10 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (1)
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study
There is limited evidence supporting the addition of everolimus to endocrine therapy in women with ER-positive/HER2-negative advanced breast cancer disease progression on CDK4/6 inhibitors. We aimed to assess the effectiveness and safety of everolimus in this setting. EVERGREEN is a multicentre, international, retrospective quasi-experimental study of women with ER-positive/HER2-negative advanced breast cancer who started an immediate next line of endocrine therapy after progression on CDK4/6 inhibitors until 31/12/2022. We compared patients exposed to endocrine therapy plus everolimus in centres where this is the standard-of-care with those treated in centres where endocrine therapy alone is the standard-of-care. The primary endpoint was real-world progression-free survival (rwPFS). Secondary endpoints were time to everolimus failure, time to chemotherapy, and overall survival. We included 207 women (everolimus n = 150, endocrine therapy alone n = 57), with a median follow-up of 31.8 months. Baseline characteristics were well balanced, except for a higher number of prior lines of therapy in the everolimus cohort. Median rwPFS was 5.0 for patients exposed to everolimus vs 4.3 months for endocrine therapy alone (adjusted hazard ratio 0.68, 95% confidence interval 0.47-0.99). Time to everolimus failure was 4.2 months. There were no statistically significant differences in time to chemotherapy or overall survival. The safety profile was consistent with previous reports. The addition of everolimus to standard endocrine therapy resulted in a modest clinical benefit for patients with ER-positive/HER2-negative advanced breast cancer candidates for endocrine therapy after CDK4/6 inhibitors. This limited benefit and the toxicity profile warrants careful selection of patients with favourable risk-benefit profile.
- 10 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (1)
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study
There is limited evidence supporting the addition of everolimus to endocrine therapy in women with ER-positive/HER2-negative advanced breast cancer disease progression on CDK4/6 inhibitors. We aimed to assess the effectiveness and safety of everolimus in this setting. EVERGREEN is a multicentre, international, retrospective quasi-experimental study of women with ER-positive/HER2-negative advanced breast cancer who started an immediate next line of endocrine therapy after progression on CDK4/6 inhibitors until 31/12/2022. We compared patients exposed to endocrine therapy plus everolimus in centres where this is the standard-of-care with those treated in centres where endocrine therapy alone is the standard-of-care. The primary endpoint was real-world progression-free survival (rwPFS). Secondary endpoints were time to everolimus failure, time to chemotherapy, and overall survival. We included 207 women (everolimus n = 150, endocrine therapy alone n = 57), with a median follow-up of 31.8 months. Baseline characteristics were well balanced, except for a higher number of prior lines of therapy in the everolimus cohort. Median rwPFS was 5.0 for patients exposed to everolimus vs 4.3 months for endocrine therapy alone (adjusted hazard ratio 0.68, 95% confidence interval 0.47-0.99). Time to everolimus failure was 4.2 months. There were no statistically significant differences in time to chemotherapy or overall survival. The safety profile was consistent with previous reports. The addition of everolimus to standard endocrine therapy resulted in a modest clinical benefit for patients with ER-positive/HER2-negative advanced breast cancer candidates for endocrine therapy after CDK4/6 inhibitors. This limited benefit and the toxicity profile warrants careful selection of patients with favourable risk-benefit profile.
- Open Access
- 22 May 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (11) , 710-717
Moral Distress, Work Engagement, and Meaningful Work in Healthcare: A Narrative Review
The psychological well-being of healthcare professionals is increasingly recognized as a critical determinant of patient safety, quality of care, and healthcare system sustainability. Among the constructs most relevant to this domain are moral distress, work engagement, and meaningful work. This narrative review aimed to synthesize conceptual and empirical evidence on these three constructs and to examine their interrelations and implications for healthcare practice. A selective narrative review of the literature was conducted, integrating theoretical frameworks, systematic and integrative reviews, and empirical studies, resulting in a final synthesis of 41 articles. Moral distress arises when clinicians are prevented from acting in accordance with their ethical convictions, often due to institutional or systemic constraints, and has been consistently associated with burnout, turnover, and compromised quality of care. In contrast, work engagement – characterized by vigor, dedication, and absorption – and meaningful work – reflecting the perception that professional activities have meaning and purpose – function as protective factors that enhance resilience and sustain intrinsic motivation. Evidence highlights the central role of organizational climate, leadership, resource availability, and ethical culture in shaping experiences of distress, engagement, and meaningfulness, a dynamic further intensified during the COVID-19 pandemic. The synthesis emphasizes that organizational and systemic interventions, including ethics consultation, supportive leadership, workflow redesign, and resilience-building programs, are essential to mitigate moral distress and promote engagement and meaningful work. The integration of these constructs aligns with the Quadruple Aim, reinforcing the premise that caring for healthcare professionals is indispensable to caring for patients.
- 22 May 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (11) , 710-717
Open AccessMoral Distress, Work Engagement, and Meaningful Work in Healthcare: A Narrative Review
The psychological well-being of healthcare professionals is increasingly recognized as a critical determinant of patient safety, quality of care, and healthcare system sustainability. Among the constructs most relevant to this domain are moral distress, work engagement, and meaningful work. This narrative review aimed to synthesize conceptual and empirical evidence on these three constructs and to examine their interrelations and implications for healthcare practice. A selective narrative review of the literature was conducted, integrating theoretical frameworks, systematic and integrative reviews, and empirical studies, resulting in a final synthesis of 41 articles. Moral distress arises when clinicians are prevented from acting in accordance with their ethical convictions, often due to institutional or systemic constraints, and has been consistently associated with burnout, turnover, and compromised quality of care. In contrast, work engagement – characterized by vigor, dedication, and absorption – and meaningful work – reflecting the perception that professional activities have meaning and purpose – function as protective factors that enhance resilience and sustain intrinsic motivation. Evidence highlights the central role of organizational climate, leadership, resource availability, and ethical culture in shaping experiences of distress, engagement, and meaningfulness, a dynamic further intensified during the COVID-19 pandemic. The synthesis emphasizes that organizational and systemic interventions, including ethics consultation, supportive leadership, workflow redesign, and resilience-building programs, are essential to mitigate moral distress and promote engagement and meaningful work. The integration of these constructs aligns with the Quadruple Aim, reinforcing the premise that caring for healthcare professionals is indispensable to caring for patients.
- Open Access
- 1 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S169
The Dynamics of Alkaline Phosphatase in Man with Metastatic Castration-Resistant Prostate Cancer and Bone Metastasis Receiving Enzalutamide: A Survivor Predictor?
- 1 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S169
Open AccessThe Dynamics of Alkaline Phosphatase in Man with Metastatic Castration-Resistant Prostate Cancer and Bone Metastasis Receiving Enzalutamide: A Survivor Predictor?
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1089
2065P Communication on the first medical oncology appointment: What do cancer patients want?
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1089
2065P Communication on the first medical oncology appointment: What do cancer patients want?
- 16 August 2016
- Published by Morressier GmbH
UTERINE SARCOMA: 13 YEARS IN A SINGLE INSTITUTION